Beijing Wantai Biological's Bivalent HPV Vaccine Gains Market Access in Multiple Southeast Asian Countries
Deep News2025-12-15
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SH) announced on December 15 that its bivalent HPV vaccine has obtained market access in several Southeast Asian countries, including Cambodia, Thailand, Myanmar, and Indonesia. The company made this statement in response to an investor inquiry on an interactive platform regarding its plans for promoting cervical cancer vaccines in Southeast Asia.
Additionally, Beijing Wantai Biological stated that its nonavalent HPV vaccine will leverage the international achievements of the bivalent HPV vaccine to establish a broader global network, further supporting the worldwide strategy to eliminate cervical cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
